Sales & Marketing News | pharmaphorum

News

Pfizer joins three-way PARP battle in prostate cancer

Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec

News

Argenx gets FDA nod for first subcutaneous gMG therapy

The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul

News

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc

News

Boehringer loses bid to be shielded from Zantac litigation

Sanofi says it has won an arbitration dispute with Boehringer Ingelheim, in which the latter had tried to protect itself from liabilities that may arise from ongoing litig

News

BMS joins Merck in challenge to Medicare price negotiation

Bristol-Myers Squibb has filed a lawsuit against the US government that aims to block the drug price negotiation elements of the Inflation Reduction Act (IRA), joining fel

News

Weight-loss drugs ‘will be a $60bn market in 10 years’

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,

Pfizer joins three-way PARP battle in prostate cancer

Argenx gets FDA nod for first subcutaneous gMG therapy

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Boehringer loses bid to be shielded from Zantac litigation

BMS joins Merck in challenge to Medicare price negotiation

Weight-loss drugs ‘will be a $60bn market in 10 years’

Policy in Focus: What’s new with CMS drug price negotiation,...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks